An interventional study of Intervention group in Uncontrolled Asthma, sponsored by AstraZeneca. Recruiting at 20 sites in China. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by AstraZeneca · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 64th largest by planned enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 with no phase, reaches primary completion later than 19 of the 27 other live ones, and was the 356th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
AstraZeneca · Sites in China
Ages 12–80
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 540 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA.
This study is a prospective, multicenter, cluster-randomized trial conducted in China, designed to evaluate the application effect of Guideline-Directed Medical Therapy (GDMT). A scientific committee will be established to be responsible for developing GDMT educational materials and facilitating the implementation of GDMT. The study will introduce a GDMT pathway in intervention group aimed at guiding physicians and specialized nurses in the diagnosis and management of participants who are receiving medium- to high-dose ICS-LABA therapy but have uncontrolled asthma.
This study plans to include approximately 60 study sites and consecutively recruit approximately 540 participants. These sites will cover as many provinces and cities as possible to balance geographical distribution. For the 60 selected sites meeting the hospital qualification requirements, a stratified block randomization method will be used, with the stratification factor being the prior written diagnosis rate for severe asthma (the proportion of severe asthma written diagnoses among patients with asthma on medium-to-high dose ICS-LABA). Sites will be randomly allocated in a 1:1 ratio to either the intervention group or the control group (30 sites per group). To minimize selection bias, each site will consecutively enroll 9 participants who meet all inclusion criteria and have provided signed informed consent. All participants must complete the baseline study assessments before entering the study. This is a cluster-randomized interventional study, with an expected duration of 48 weeks. The intervention is implemented at the hospital level. Participants in the two groups will be managed as follows:
Participant data (including but not limited to: demographic characteristics, number of exacerbations, asthma medication use, ACT scores, pulmonary function, SGRQ scores, medical costs) will be collected according to the Schedule of Study Activities.
The benefits and effectiveness of GDMT will be determined by assessing changes in physician behavior, improvements in patient outcomes, and savings in healthcare resources.
The intervention consists of 5 distinct components: routine training, GDMT education, clinical monitoring, targeted training, and material revision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exacerbation is defined as meeting any of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention will be implemented at the hospital level.
Behavioral: Intervention group
No intervention action will be taken at hospital level, even patient level.
The GDMT pathway targets physicians and specialized nurses for implementation. It ensures that physicians at intervention groups conduct standardized diagnosis and treatment following GDMT, and that specialized nurses deliver patient education and follow-up reminders according to GDMT. This is achieved through regular knowledge training, provision of a series of reminder/support tools, and a bi-weekly (every 12 weeks) monitoring, and feedback system for Key Performance Indicators (KPIs).
Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24
To evaluate the effect of GDMT education on diagnosis rates of severe asthma
Time frame: Week 24
Difference in the annualized asthma exacerbation rate between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on asthma exacerbations
Time frame: Week 48
Difference in the proportion of participants with asthma exacerbation between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on asthma control
Time frame: Week48
Difference in the change in mean ACT score from baseline between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on asthma control
Time frame: Baseline, week 48
Change in mean ACT score from baseline in the intervention group at Week 24 and 48
To evaluate the effect of GDMT education on asthma control
Time frame: Baseline, week 24, week 48
Change in the proportion of participants achieving asthma symptom control (ACT ≥20) from baseline in the intervention group at Week 24 and 48
To evaluate the effect of GDMT education on asthma control
Time frame: Baseline, week 24, week 48
Difference in the proportion of participants with asthma symptom control (ACT ≥20) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on asthma control
Time frame: Week 48
Difference in the proportion of participants achieved the Minimal Clinically Important Difference (MCID) in asthma symptom control (ACT improvement ≥3 points) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on asthma control
Time frame: Week 48
The proportion of participants achieved ACT MCID (ACT improvement ≥3 points) in the intervention group at Week 24 and 48
To evaluate the effect of GDMT education on asthma control
Time frame: Week 24, week 48
Difference in pre-bronchodilator Forced Expiratory Volume in 1 second (Pre-BD FEV1) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on pulmonary function
Time frame: Week 48
Change in pre-bronchodilator FEV1 (Pre-BD FEV1) from baseline in the intervention group at Week 24 and 48
To evaluate the effect of GDMT education on pulmonary function
Time frame: Baseline, week 24, week 48
Difference in the proportion of participants with combined persistent airflow obstruction (PAO, FEV1/FVC <70%) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on pulmonary function
Time frame: Week 48
Difference in St. George's Respiratory Questionnaire (SGRQ) scores (total and domain scores) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on quality of life
Time frame: Week 48
Change in SGRQ scores from baseline in the intervention group at Week 24 and Week 48
To evaluate the effect of GDMT education on quality of life
Time frame: Baseline, week 24, week 48
Difference in the proportion of participants who achieved SGRQ MCID (decrease in total score ≥4 points) between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on quality of life
Time frame: Week 48
The proportion of participants achieved SGRQ MCID (decrease in total score ≥4 points) in the intervention group at Week 24 and 48
To evaluate the effect of GDMT education on quality of life
Time frame: Week 24, week 48
Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on diagnosis rate
Time frame: Week 48
Difference in the time to written diagnosis of "Severe Asthma" between the intervention and control groups during the 48-week study period;
To evaluate the effect of GDMT education on diagnosis rate
Time frame: During the 48-week study period
Reasons for not meeting the diagnostic criteriac for severe asthma among participants in the intervention group not diagnosed with "severe asthma" at Week 48
To evaluate the effect of GDMT education on diagnosis rate
Time frame: Week 48
Difference in the proportion of participants with peripheral blood eosinophil (bEOS) test records within the past 3 months, excluding those during asthma exacerbation, between the intervention and control groups at Week 24 and 48
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: Week 24, week 48
Difference in the proportion of participants with Fractional exhaled Nitric Oxide (FeNO) test records within the past 3 months between the intervention and control groups at Week 24 and 48
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: Week 24, week 48
Difference in the proportion of participants with Immunoglobulin E (IgE) test records within the past 3 months between the intervention and control groups at Week 24 and 48
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: Week 24, week 48
Difference in the cumulative number of bEOS test records between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: During the 48-week study period
Difference in the cumulative number of IgE test records between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: During the 48-week study period
Difference in the cumulative number of FeNO test records between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on biomarkers tests rate
Time frame: During the 48-week study period
Difference in the proportion of participants with typing records between the intervention and control groups over the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: Week 48
Difference in the time to first asthma typing record between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: During the 48-week study period
Difference in the proportion of participants with record of eosinophilic asthma phenotype between the intervention and control groups over the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: Week 48
Difference in the time to first eosinophilic asthma phenotype record between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: During the 48-week study period
Difference in the proportion of participants with a recorded Type 2 (T2) asthma phenotype between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: Week 48
Difference in the proportion of participants with record of allergic asthma phenotype between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on typing records
Time frame: Week 48
Difference in the cumulative number of pulmonary function test records between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on pulmonary function test utilization
Time frame: Week 48
Difference in the proportion of participants using biologics between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on biologic utilization
Time frame: Week 48
Difference in the duration of biologic use between the intervention and control groups
To evaluate the effect of GDMT education on biologic utilization
Time frame: During the 48-week study period
Distribution of different treatment pattern in the intervention group during the 48-week study period
To evaluate the effect of GDMT education on treatment pattern
Time frame: During the 48-week study period
Distribution of different treatment pattern in the control group at Week 48
To evaluate the effect of GDMT education on treatment pattern
Time frame: Week 48
Difference in the proportion of participants regularly completing scheduled follow-ups visitse between the intervention and control groups over the 48-week study period
To evaluate the effect of GDMT education on regular follow-up visits
Time frame: Week 48
Difference in the drop-out rate between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on regular follow-up visits
Time frame: Week 48
Subgroup analyses will be conducted as appropriate; planned subgroups to explore include: Hospital classification, Participant classification.
Describe the differences in physician behavior, participant benefit, and healthcare resource conservation across different hospital and participant subgroups after GDMT education
Time frame: During the 48-week study period
Difference in the proportion of participants achieving clinical remission of asthma (CR3/CR4)f between the intervention and control groups at Week 48
To evaluate the effect of GDMT education on clinical remission of asthma
Time frame: Week 48
Characteristics of participants using biologics during the study period, including age, gender, disease duration, MH, insurance type, annual household income, asthma symptoms, comorbidities, EOS/FeNO/IgE levels, pulmonary function etc.
To describe the characteristics of participants using biologics
Time frame: During the 48-week study period
Proportion of participants receiving maintenance OCS therapyi at Week 24 and 48
To assess the effect of GDMT education on oral corticosteroid (OCS) use
Time frame: Week 24, week 48
Difference in the accumulative dose of maintenance OCS received between the intervention and control groups at Week 24 and 48
To assess the effect of GDMT education on oral corticosteroid (OCS) use
Time frame: Week 24, week 48
Difference in the reduction of maintenance OCS dose among biologic users between the intervention and control groups at Week 48
To assess the effect of GDMT education on oral corticosteroid (OCS) use
Time frame: Week 48
Difference in proportion of participants with asthma-related hospitalization between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: Week 48
Difference in the average annual asthma-related hospitalization frequency between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the average annual length of asthma-related hospital stay between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in proportion of participants with asthma-related ICU stay between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the average annual length of asthma-related ICU stay between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in proportion of participants with asthma-related emergency department visits between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the average number of emergency department visits between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the number of prescribed medications types between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the average annualized asthma-related medical costsj between the intervention and control groups during the 48-week study period
To assess the effect of GDMT education on healthcare resource utilization
Time frame: During the 48-week study period
Difference in the change from baseline in Impulse Oscillometry (IOS) parameters (R5, R20, X5, Fres, AX) between the intervention and control groups at Week 24 and 48
To evaluate the effect of GDMT education on pulmonary function (IOS)
Time frame: Week 24, week 48
Reasons for not initiating biologics in participants with severe asthma in the intervention group during the study period
To describe reasons for not initiating biologics in severe asthma during the study period, and reasons for participants discontinuing biologics
Time frame: During the 48-week study period
Reasons for discontinuing biologics in intervention group during the study period
To describe reasons for not initiating biologics in severe asthma during the study period, and reasons for participants discontinuing biologics
Time frame: During the 48-week study period
Difference in number of asthma-related comorbidities typesk in written records between the intervention and control groups during the 48-week study period
To evaluate the effect of GDMT education on comorbidity recording
Time frame: During the 48-week study period
Treatment satisfaction in the intervention and control groups at Week 48
To evaluate the effect of GDMT education on participant treatment satisfaction
Time frame: Week 48
Started Sep 2026 (actual). Primary completion is estimated for Apr 2028, 19 months after the start.
Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 19 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.